RAF: Perioperative Residual Adrenal Function After Extended Resection for Retroperitoneal Soft Tissue Sarcomas

Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Other)
Overall Status
Completed
CT.gov ID
NCT04225494
Collaborator
(none)
52
1
23.7
2.2

Study Details

Study Description

Brief Summary

Early recognition of adrenal function deficit in patients undergoing multivisceral surgery including adrenalectomy for primitive retroperitoneal sarcomas

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The extended multivisceral resection of retroperitoneum is the standard treatment for primary retroperitoneal soft tissue sarcomas. This procedure also includes the removal of the healthy adrenal gland ipsilateral to the tumor site.

    The investigators think that a such extended surgical approach together with the removal of the adrenal gland may lead to a state of acute adrenal insufficiency and related hemodynamic instability.

    In order to recognize this condition the investigators use a low dose ACTH test (Synacthen test) during the 1° and 10° post-operative days.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    52 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of Perioperative Residual Adrenal Function After Extended Multivisceral Resection for Primary Retroperitoneal Soft Tissue Sarcomas: a Prospective Observational Study
    Actual Study Start Date :
    Jun 1, 2019
    Actual Primary Completion Date :
    Aug 31, 2020
    Actual Study Completion Date :
    May 21, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Serum Cortisol peak after low dose Synachten stimulation test. [1st postoperative day]

      Assessment of early postoperative acute adrenal dysfunction.

    2. Serum Cortisol peak after low dose Synachten stimulation test. [10th postoperative day]

      Assessment of postoperative acute adrenal dysfunction.

    3. Serum Cortisol peak after low dose Synachten stimulation test. [4 months after surgery (only if test positive on 10th postoperative day)]

      Assessment of postoperative chronic adrenal dysfunction.

    Secondary Outcome Measures

    1. Postoperative morbidity [30th postoperative day]

      Correlation between morbidity according to Clavien-Dindo and postoperative adrenal dysfunction

    2. Vasoactive inotropic score [Intraoperatively and up to 3rd postoperative day]

      Correlation between intra- and postoperative usage of vasoactive drugs and postoperative adrenal dysfunction

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients (age> 18 years)

    • Diagnosis of retroperitoneal sarcoma

    • Adrenalectomy enbloc included in multivisceral resection

    • Voluntary informed written consent

    Exclusion Criteria:
    • Recurrent and / or metastatic disease

    • Patient chronically treated with corticosteroids

    • Primary disorders of adrenal gland

    • Basal serum cortisol values ≤ 7 µg / dL

    • Clinically significant heart disease

    • Altered TSH

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fondazione IRCCS Istituto Nazionale dei Tumori Milan Lombardia Italy 20133

    Sponsors and Collaborators

    • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Marco Fiore, Principal Investigator, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    ClinicalTrials.gov Identifier:
    NCT04225494
    Other Study ID Numbers:
    • 64/19
    First Posted:
    Jan 13, 2020
    Last Update Posted:
    Oct 5, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Marco Fiore, Principal Investigator, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 5, 2021